Is the News About a Cancer Vaccine That Eliminates Tumors True? What Is Amivantamab Really, and What Is It Not?

First, let us clarify: What is the truth behind this news?

The reports are based on head and neck cancer cohort data, presented at ASCO 2026 and published concurrently, from the OrigAMI-4 study. It evaluated subcutaneous amivantamab, meaning administered under the skin, in patients with recurrent or metastatic head and neck squamous cell carcinoma unrelated to HPV who had previously received immunotherapy and platinum-based chemotherapy.

The results are indeed noteworthy: the confirmed objective response rate according to independent central review was %42 ; approximately %15 of patients had a complete response . Median progression-free survival was 6,8 months, and median overall survival was 12,5 months . This is an important clinical signal for a group of patients with very limited treatment options.

What is amivantamab, and how does it differ from a vaccine?

Amivantamab, marketed as Rybrevant / Rybrevant Faspro, is a bispecific antibody that binds to two different targets called EGFR and MET. EGFR and MET are signaling pathways associated with growth, proliferation, spread and treatment resistance in some cancer cells. By targeting both pathways simultaneously, amivantamab aims to suppress tumor growth signaling and increase immune-cell activity against the tumor.

Vaccines, by contrast, teach the immune system about a target; they generally aim to generate a protective or, in certain cancers, therapeutic immune response. Amivantamab does not work this way. The patient is not vaccinated; the drug binds directly to EGFR/MET targets on the tumor cell.

The difference between the social-media claim and scientific reality

The OrigAMI-4 study: In which patients was it tested?

OrigAMI-4 is an open-label phase 1b/2 study evaluating subcutaneous amivantamab alone or in various combinations in recurrent or metastatic head and neck squamous cell carcinoma. The data discussed on social media are the results of cohort 1 of this study.

This cohort included 102 patients . Patients had previously received both an immune checkpoint inhibitor and platinum-based chemotherapy. Patients with HPV-positive oropharyngeal cancer and those previously treated with anti-EGFR therapy were not included in this cohort. This detail is very important because the study results apply to a specific, selected patient group.

What did the results show?

The confirmed objective response rate according to independent central review was %42 . This rate refers to patients whose tumors showed marked shrinkage or disappeared on imaging. Of the responses, %15 were complete responses, %27 were partial responses . The clinical benefit rate was %63 .

The median time to first response was 6,6 weeks . The fact that median duration of response had not yet been reached indicates that some responses were ongoing at data cutoff. Median progression-free survival was 6,8 months, and median overall survival was 12,5 months .

What does “the tumor disappeared in 15 patients” mean?

One of the most prominent media statements is “the tumor completely disappeared in 15 patients”. Its scientific meaning is this: the study reported approximately %15 complete responses . This means that tumor lesions disappeared on imaging or in the assessment of measurable disease.

However, in oncology a complete response does not always mean “the patient is definitely cured” or “the cancer has been completely cleared from the body”. Especially in metastatic disease, microscopic disease may remain and the risk of recurrence may persist over time. Therefore, phrases such as “eradicated it”, “eliminated it” and “miracle vaccine” can create unrealistic expectations for patients and their relatives.

Safety: Side effects are mostly mild to moderate, but require monitoring

The safety profile of subcutaneous amivantamab monotherapy was consistent with previous amivantamab experience, and no new safety signal was reported. Most treatment-related adverse events were grade 1–2, meaning mild to moderate. The most frequently reported on-target side effects were hypoalbuminemia %50, rash %37, paronychia %34 and acneiform dermatitis %34 .

Administration-related reactions %15 were reported at this rate, and no grade 3 or higher administration reactions were reported. The rate of treatment discontinuation due to treatment-related adverse events was %8 . Although this safety profile is promising, experienced monitoring is required, especially for EGFR/MET-related skin and nail effects, edema, low albumin and gastrointestinal side effects.

Regulatory status: Is it FDA approved?

The FDA had approved amivantamab for advanced NSCLC with EGFR exon 20 insertion mutations in combination with chemotherapy in the first line and as monotherapy after platinum treatment. It also has other NSCLC indications, including combinations with lazertinib and chemotherapy in advanced NSCLC with EGFR exon 19 deletions or L858R mutations. The subcutaneous formulation has been approved to cover the approved NSCLC indications of intravenous amivantamab.

What was new at ASCO 2026?

Yes, more mature and noteworthy data from the OrigAMI-4 study of amivantamab in head and neck cancer were presented at ASCO 2026. This is the source of the media reports. However, the new data do not mean that “a vaccine for all cancers has been found”.

The same program also reported that the phase 3 study called OrigAMI-5 was ongoing. OrigAMI-5 aims to compare subcutaneous amivantamab combined with pembrolizumab and carboplatin against the standard pembrolizumab + platinum + 5-FU regimen in first-line recurrent/metastatic head and neck cancer. The scientific process is therefore continuing; the drug’s true place in head and neck cancer will be clarified by phase 3 data.

Why are these data still important?

When head and neck squamous cell carcinoma recurs or metastasizes, options are limited, especially after immunotherapy and platinum-based chemotherapy. Response rates with existing later-line treatments are generally low, and complete responses are rare. A confirmed ORR of %42 and complete response of %15 are therefore noteworthy for this group.

Subcutaneous administration also matters in practice. Intravenous amivantamab can be challenging for patients and clinics because of its long infusion time and infusion reactions. The subcutaneous formulation may shorten administration time and reduce the workload of treatment centers. However, convenient administration does not mean the treatment is a “vaccine”.

Critical reading: How should this news be interpreted in a balanced way?

How should we answer patients in the clinic?

When patients call asking, “Doctor, is this vaccine suitable for us?”, the most accurate response should follow this framework: This is not a vaccine but a targeted antibody treatment. It is not currently used as a routinely approved standard treatment for head and neck cancer in Türkiye or worldwide. It is approved for certain EGFR mutations in lung cancer. The head and neck cancer data are promising, but remain at the clinical research stage.

Which patients should be interested in these data?

The OrigAMI-4 data particularly concern patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma who previously received platinum-based chemotherapy and PD-1/PD-L1 immunotherapy, whose disease progressed after these treatments and who had no history of anti-EGFR therapy.

It is unknown whether the same efficacy can be expected in patients outside these criteria. For example, HPV-positive oropharyngeal cancer, patients previously treated with anti-EGFR therapy, earlier-stage disease, candidates for surgery/radiotherapy and other cancer types are not groups for which direct conclusions can be drawn from these data.

Conclusion

The headline “a cancer vaccine that eliminates tumors”, circulating on social media about amivantamab, is not scientifically accurate. Amivantamab is not a vaccine but an EGFR- and MET-targeted bispecific monoclonal antibody. Its existing FDA approvals are for EGFR-mutant non-small cell lung cancer; it is not currently an approved standard treatment for head and neck cancer.

Nevertheless, the OrigAMI-4 data presented at ASCO 2026 are important. In HPV-unrelated recurrent/metastatic head and neck cancer previously treated with platinum-based chemotherapy and immunotherapy, subcutaneous amivantamab monotherapy showed a BICR-assessed confirmed ORR of %42, complete response of %15, median PFS of 6,8 months and median OS of 12,5 months.

These findings suggest that a new treatment pathway may open for the appropriate patient group. However, the best approach for patients is to view the drug not as a “miracle vaccine” but as a promising targeted antibody treatment whose research and regulatory processes are still ongoing.